LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection

    Toni Herta / Magdalena Hahn / Melanie Maier / Janett Fischer / Johannes Niemeyer / Mario Hönemann / Albrecht Böhlig / Florian Gerhardt / Aaron Schindler / Jonas Schumacher / Thomas Berg / Johannes Wiegand / Florian van Bömmel

    Pathogens, Vol 11, Iss 517, p

    2022  Volume 517

    Abstract: Background: The hepatitis B and D virus (HBV/HDV) hepatocyte entry inhibitor bulevirtide (BLV) has been available in Europe since July 2020, after the registrational trial MYR202. Real-life data on the efficacy and safety of BLV are sparse. Methods: We ... ...

    Abstract Background: The hepatitis B and D virus (HBV/HDV) hepatocyte entry inhibitor bulevirtide (BLV) has been available in Europe since July 2020, after the registrational trial MYR202. Real-life data on the efficacy and safety of BLV are sparse. Methods: We have analysed the course of treatment with BLV (2 mg/day) plus tenofovir disoproxil fumarate (TDF) (245 mg/day) in patients with chronic hepatitis delta (CHD). Virologic (≥2 log reduction in HDV RNA or suppression of HDV RNA below the lower limit of detection) and biochemical (normalisation of serum ALT) treatment responses after 24 weeks were defined according to the MYR202 trial. Results: Seven patients were recruited (four with liver cirrhosis Child–Pugh A). After 24 weeks, a virologic response was observed in five of seven and a biochemical response was seen in three of six patients with elevated serum ALT at baseline. Extended treatment data > 48 weeks were available in three cases: two presented with continuous virologic and biochemical responses and in one individual an HDV-RNA breakthrough was observed. Adverse effects were not recorded. Conclusions: The first real-life data of the approved dosage of 2 mg of BLV in combination with TDF confirm the safety, tolerability, and efficacy of the registrational trial MYR202 for a treatment period of 24 weeks and beyond.
    Keywords bulevirtide ; tenofovir disoproxil fumarate ; hepatitis delta ; treatment response ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2022-04-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Article ; Online: Calcium-sensing receptor-mediated NLRP3 inflammasome response to calciprotein particles drives inflammation in rheumatoid arthritis

    Elisabeth Jäger / Supriya Murthy / Caroline Schmidt / Magdalena Hahn / Sarah Strobel / Anna Peters / Claudia Stäubert / Pelin Sungur / Tom Venus / Mandy Geisler / Veselina Radusheva / Stefanie Raps / Kathrin Rothe / Roger Scholz / Sebastian Jung / Sylke Wagner / Matthias Pierer / Olga Seifert / Wenhan Chang /
    Irina Estrela-Lopis / Nora Raulien / Knut Krohn / Norbert Sträter / Stephanie Hoeppener / Torsten Schöneberg / Manuela Rossol / Ulf Wagner

    Nature Communications, Vol 11, Iss 1, Pp 1-

    2020  Volume 17

    Abstract: How extracellular calcium can trigger Nlrp3 inflammasome activation has been somewhat controversial and unclear. Here the authors show calciprotein particles are taken up by myeloid cells via calcium-sensing receptor-dependent macropinocytosis in ... ...

    Abstract How extracellular calcium can trigger Nlrp3 inflammasome activation has been somewhat controversial and unclear. Here the authors show calciprotein particles are taken up by myeloid cells via calcium-sensing receptor-dependent macropinocytosis in response to high levels of extracellular Ca2+ and this pathway might be critical to inflammatory conditions.
    Keywords Science ; Q
    Language English
    Publishing date 2020-08-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: Calcium-sensing receptor-mediated NLRP3 inflammasome response to calciprotein particles drives inflammation in rheumatoid arthritis

    Elisabeth Jäger / Supriya Murthy / Caroline Schmidt / Magdalena Hahn / Sarah Strobel / Anna Peters / Claudia Stäubert / Pelin Sungur / Tom Venus / Mandy Geisler / Veselina Radusheva / Stefanie Raps / Kathrin Rothe / Roger Scholz / Sebastian Jung / Sylke Wagner / Matthias Pierer / Olga Seifert / Wenhan Chang /
    Irina Estrela-Lopis / Nora Raulien / Knut Krohn / Norbert Sträter / Stephanie Hoeppener / Torsten Schöneberg / Manuela Rossol / Ulf Wagner

    Nature Communications, Vol 11, Iss 1, Pp 1-

    2020  Volume 17

    Abstract: How extracellular calcium can trigger Nlrp3 inflammasome activation has been somewhat controversial and unclear. Here the authors show calciprotein particles are taken up by myeloid cells via calcium-sensing receptor-dependent macropinocytosis in ... ...

    Abstract How extracellular calcium can trigger Nlrp3 inflammasome activation has been somewhat controversial and unclear. Here the authors show calciprotein particles are taken up by myeloid cells via calcium-sensing receptor-dependent macropinocytosis in response to high levels of extracellular Ca2+ and this pathway might be critical to inflammatory conditions.
    Keywords Science ; Q
    Language English
    Publishing date 2020-08-01T00:00:00Z
    Publisher Nature Publishing Group
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top